Side-by-side · Research reference

DihexavsEpitalon

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

AAnimal-StrongHUMAN-REVIEWED7/28 cited

BHuman-MechanisticAUTO-DRAFTED8/37 cited

Dihexa

Angiotensin IV Analogue · Pre-Clinical

Pre-clinicalDevelopment stage

Rodent onlyEvidence basisBenoist 2014

HGF/c-MetTarget systemWright 2015

Not established — animal studies only

Epitalon

Pineal bioregulator · Telomerase activator

5–10 mgPer cycle doseKhavinson 2003

HumanMechanisticKhavinson 2003

HoursHalf-life (est)

SQ or IM · Abdomen · Daily for 10–20 days

01Mechanism of Action

Parameter

Dihexa

Epitalon

Primary target

c-Met receptor (HGF receptor tyrosine kinase)

Telomerase activity (proposed); pineal melatonin axis modulationKhavinson 2003

Pathway

HGF/c-Met receptor activation → downstream signaling cascade → synaptogenesis and dendritic arborization

Activation of telomerase reverse transcriptase (hTERT) in somatic cells; pineal-axis modulation supports endogenous melatoninKhavinson 2003

Downstream effect

Induction of dendritic arborization, synapse formation, neurogenesis, and neuroprotection in rodent models

Telomere elongation, improved sleep architecture, reported lifespan extension in aged miceKhavinson 2003

Feedback intact?

—

Origin

Small-molecule angiotensin IV analogue designed to activate HGF/c-Met systemWright 2015

Synthetic 4-AA peptide derived from epithalamin (a natural pineal extract)Khavinson 2003

Antibody development

—

02Dosage Protocols

Parameter

Dihexa

Epitalon

Human dosing

Not established — no human trials

—

Animal studies

Mouse/rat models only — dosing not translatable to humans

—

Evidence basis

Pre-clinical / Rodent models

In-vitro telomerase + Russian clinical trialsKhavinson 2003

Clinical status

No Phase 1, 2, or 3 trials published

—

Standard dose

—

5–10 mg / day for 10–20 days, 1–2× per yearKhavinson 2003

Anecdotal community protocol. Russian clinical literature uses similar cycling.

Frequency

—

Once daily during a cycle

Lower / starter dose

—

2.5 mg / day

Duration

—

10–20 day cycles, 1–2× per year

Reconstitution

—

Bacteriostatic water

Timing

—

Pre-sleep preferred (pineal alignment)

Half-life

—

Hours (estimated)

04Side Effects & Safety

Parameter

Dihexa

Epitalon

Human safety data

None available — no human clinical trials

—

Theoretical c-Met risks

c-Met receptor activation has been implicated in tumorigenesis; unknown cancer risk profile

—

Pre-clinical tolerability

Not systematically reported in available studies

—

Injection site reaction

—

Mild irritation

Sleep architecture

—

Improved subjective sleep quality (anecdotal)

Cancer risk

—

Theoretical via telomerase activation in pre-malignant cells

Long-term safety

—

Limited Western RCT data

Pregnancy / OB

—

Avoid

Antibody formation

—

Not reported

Absolute Contraindications

Dihexa

·Not approved for human use — research compound only

Epitalon

·Pregnancy / breastfeeding
·Active malignancy or pre-malignant state

Relative Contraindications

Dihexa

·Theoretical contraindication: active or history of malignancy (c-Met pathway involvement in cancer)

Epitalon

·Family history of cancer

05Administration Protocol

Parameter

Dihexa

Epitalon

1. Human administration

No established protocol. Dihexa has not been tested in human subjects. Animal studies used various routes (typically subcutaneous or intraperitoneal in rodents) not translatable to clinical use.

Add 1–2 mL bacteriostatic water to 10 mg vial → 5–10 mg/mL.

2. Legal status

Pre-clinical research compound. Not approved by FDA or any regulatory authority for human use.

SQ — abdomen preferred. Rotate sites.

3. Timing

—

Pre-sleep preferred to align with pineal axis.

4. Storage

—

Lyophilised: room temp, light-protected. Reconstituted: refrigerate ≤30 days.

5. Needle

—

29–31G, 4–8 mm insulin syringe.